What is Monte Rosa Therapeutics, Inc.'s net margin?

Monte Rosa Therapeutics, Inc. (GLUE) reported net margin of -302.6% in Q1 2026.

What does net margin mean?

Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.

Monte Rosa Therapeutics, Inc. GLUE Net margin

Net margin at other companies

Bristol-Myers SquibbBMY

15%+3.8pp

Nurix Therapeutics, Inc.NRIX

-411.4%+52.7pp

Kymera TherapeuticsKYMR

-612%+602pp

ImmunomeIMNM

-5,593.8%-11,284pp

Adaptive BiotechnologiesADPT

-16.8%-7.3pp

Arcus BiosciencesRCUS

-156.4%-47.5pp

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

net income/total revenue=-302.6%

Based on trailing twelve months.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s net margin?: Monte Rosa Therapeutics, Inc. (GLUE) reported net margin of -302.6% in Q1 2026.
What does net margin mean?: Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.